Johnson & Johnson Vision News

Johnson & Johnson Vision News

Johnson & Johnson Vision on Track for Multinational Launch of New Contact Lens Innovation: ACUVUE® OASYS MAX 1-Day

Johnson & Johnson Vision has received approval from the U.S. Food & Drug Administration (FDA), European Commission and Health Canada for its latest contact lens innovation, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL. 

The new contact lenses were developed to provide all day comfort and visual clarity amidst feedback from eye care professionals and patients that today’s modern lifestyles, long hours and increased use of digital devices are taking a toll on eye comfort. A recent survey found the majority (71%) of eye care professionals are seeing patients who are experiencing eye discomfort related to increased screen-time, with young contact lens wearers spending an average of 9 hours per day in front of a screen, causing them to blink less and experience more dryness and eye fatigue. 

Available in spherical and multifocal, ACUVUE® OASYS MAX 1-Day contact lenses are designed to address multiple vision correction needs. They will be a premium range of daily disposable contact lenses designed for proven performance. The new lenses are anticipated to be made available in the US, Canada and multiple European countries in the fall of 2022.

To learn more, visit